Sanofi Plavix Superiority Claims Over Aspirin Draw Second FDA Letter
Executive Summary
FDA's ad division has issued a second letter to Sanofi-Synthelabo citing the company for making superiority claims for its antiplatelet drug Plavix versus aspirin.